Payment overview · 2025
General Payments
$377.87
12 reported records · 11 companies
Healthcare provider profile · identity verified
Michael B Wiseman, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · OAK RIDGE, TN · NPI 1689637340
Verified facts
What the public records show
CMS Open Payments records show Michael B Wiseman, FNP received $377.87 in general payments during 2025 across 12 reported records.
Regeneron Healthcare Solutions, Inc. accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 399 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $121.18 | 32.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.01 | 13.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.91 | 9.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.38 | 7.0% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $24.19 | 6.4% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $23.60 | 6.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $21.77 | 5.8% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.68 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.35 | 5.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.52 | 4.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.28 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.87 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Healthcare Solutions, Inc. | $121.18 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.01 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 399 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
399 | 78 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 399 | 78 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 398 | 90 |
| Tresiba Flextouch U-200 | Insulin Degludec | 300 | 66 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 230 | 46 |
| Novolog Flexpen | Insulin Aspart | 206 | 74 |
| Mounjaro | Tirzepatide | 189 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 47 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 158 | 38 |
| Jardiance | Empagliflozin | 156 | 31 |
| Novolog | Insulin Aspart | 109 | 22 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 108 | 37 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 102 | 43 |
| Glimepiride | Glimepiride | 97 | 26 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 95 | 15 |
| Trulicity | Dulaglutide | 94 | 23 |
| Metformin Hcl Er | Metformin Hcl | 88 | 34 |
| Rybelsus | Semaglutide | 85 | 21 |
| Humulin R U-500 | Insulin Regular, Human | 82 | 14 |
| Metformin Hcl | Metformin Hcl | 75 | 23 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 73 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 68 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | 17 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 61 | 20 |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 51 | 11 |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 50 | 13 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 46 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 42 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 41 | 13 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 34 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 31 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 31 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Gabapentin | Gabapentin | 30 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 30 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 28 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 24 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 24 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Lisinopril | Lisinopril | 22 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Losartan Potassium | Losartan Potassium | 21 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Cequr Simplicity | Bolus Insulin Pump, 200 Unit | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.87 · 12 records | Regeneron Healthcare Solutions, Inc. | AFREZZA, CeQur Simplicity, Dexcom G6 Transmitter, EYLEA HD, FREESTYLE LIBRE 3, GVOKE HYPOPEN, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, t:slim X2 Insulin Pump with Control-IQ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error